UnifiedACB

Medication evidence profile

Duloxetine

Ask about Duloxetine

Clinical overview

Duloxetine has public medication-list entries in JARS 2025, Yamada-ABS 2023, Swe-ABS 2023, GABS 2018, and KABS 2020 open validation supplement. These are 5 separate source versions, each with its own evidence and definitions.

Source-specific scores

SourceScore
JARS1
Yamada-ABS1
BAASNot listed
Swe-ABS0
GABS0
KABS0
CALSNot listed

How to read this: 0 means the source explicitly assigned zero. “Not listed” means the source did not provide a score for this medication. Scores from different scales are not averaged.

How to interpret the evidence

5 of 7 public source versions contain an explicit medication-list entry for duloxetine.

The recorded values differ across the source rows for duloxetine. Scale methods, definitions, source eras, evidence types and identity handling can differ; the numbers alone do not establish the reason for this medication’s disagreement.

Swe-ABS 2023, GABS 2018, and KABS 2020 open validation supplement explicitly record zero. Those recorded zeros remain different from a missing entry.

Source labels and provenance · 5 observations
  1. Japanese Anticholinergic Risk Scale (JARS) 2025 English translation

    Source label: Duloxetine. Published value: 1.
    Source version: JARS-2025
    Source location: RC4 source recovery; recovery_scope=primary_table_complete; ATC=N06AX21
    Observation: JARS_2025_R0041; rating state: published_rating.

  2. Yamada Pharmacological Anticholinergic Burden Scale 2023

    Source label: Duloxetine. Published value: 1.
    Source version: YAMADA-ABS-2023
    Source location: RC4 source recovery; recovery_scope=primary_nonzero_complete
    Observation: YAMADA_ABS_2023_R0004; rating state: published_rating.

  3. Swedish Anticholinergic Burden Scale 2023

    Source label: Duloxetine. Published value: 0.
    Source version: SWE-ABS-2023
    Source location: 12877_2023_4225_MOESM1_ESM.docx ST3 row 74
    Observation: SWE_ABS_2023_R0199; rating state: published_zero.

  4. German Anticholinergic Burden Score 2018

    Source label: Duloxetine. Published value: 0.
    Source version: GABS-2018
    Source location: 12877_2018_929_MOESM1_ESM.docx Table S3 row 97
    Observation: GABS_2018_R0247; rating state: published_zero.

  5. KABS 2019 scale - 2020 open validation supplement

    Source label: Duloxetine. Published value: 0.
    Source version: KABS-2020-validation-supplement
    Source location: Additional file 1; category Antidepressants; table row 10
    Observation: KABS2020_SUPP_0036; rating state: published_zero.

What this page does not establish

  • No medication-list entry is available here from BAAS 2019 and CALS 2022 Table 4. These gaps remain “Not listed”; no score is inferred from another source or from class membership.
  • No route inference unless present in the source label.
  • These source records do not estimate an individual’s probability of harm or establish whether to start, stop or change a medication. Ordinal source scores are not averaged into a UnifiedACB score.

References

  1. Mizokami F, Mizuno T, Taguchi R, et al. Development of the Japanese Anticholinergic Risk Scale: English translation of the Japanese article. Geriatr Gerontol Int. 2025;25(1):5-13. doi:10.1111/ggi.15001. Open source
  2. Yamada S, Mochizuki M, Chimoto J, Futokoro R, Kagota S, Shinozuka K. Development of a pharmacological evidence-based anticholinergic burden scale for medications commonly used in older adults. Geriatr Gerontol Int. 2023;23(7):558-564. doi:10.1111/ggi.14619. Open source
  3. Rube T, Ecorcheville A, Londos E, Modig S, Johansson P. Development of the Swedish anticholinergic burden scale (Swe-ABS). BMC Geriatr. 2023;23(1):518. doi:10.1186/s12877-023-04225-1. Open source
  4. Kiesel EK, Hopf YM, Drey M. An anticholinergic burden score for German prescribers: score development. BMC Geriatr. 2018;18(1):239. doi:10.1186/s12877-018-0929-6. Open source
  5. Suh Y, Ah YM, Han E, et al. Dose response relationship of cumulative anticholinergic exposure with incident dementia: validation study of Korean anticholinergic burden scale. BMC Geriatr. 2020;20(1):265. doi:10.1186/s12877-020-01671-z. Open source

Ask a follow-up

Go to your medication comparison · How UnifiedACB handles disagreement

Ask about this medication

Medication context: Duloxetine

Ask about this medication
Show Duloxetine across all available scalesWhy do the scales differ for Duloxetine?Show the evidence for DuloxetineCompare Duloxetine with another medication